Abstract
A pregnant young woman with a severe migraine is prescribed candesartan, an angiotensin II type 1 receptor antagonist (AT II antagonists). This has a positive effect—except for severe maldevelopment of her fetus. There is an increase in the use of the fetotoxic drugs, AT II antagonists and angiotensin-converting enzyme inhibitors, as prophylactic treatment of migraines, in addition to their use as hypertensives.
Keywords: Migraine, Pregnancy, Fetotoxic medication, Angiotensin II receptor antagonist, Angiotensin-converting enzyme inhibitor, Hypertension
Full Text
The Full Text of this article is available as a PDF (101.1 KB).
Conflict of interest
None.
Glossary
- AT II antagonist
Angiotensin II receptor antagonists
- ACE-inhibitors
Angiotensin-converting enzyme inhibitors
References
- 1.Kato K, Okuda M, Ishikawa H, Takahashi T, Hirahara F. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected. J Obstet Gynaecol Res. 2008;34(2):242–246. doi: 10.1111/j.1447-0756.2008.00762.x. [DOI] [PubMed] [Google Scholar]
- 2.Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of ten cases. BJOG. 2005;112(6):710–712. doi: 10.1111/j.1471-0528.2004.00525.x. [DOI] [PubMed] [Google Scholar]
- 3.Regional medicines information centres. Norwegian database of adverse effects
- 4.Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007;47(Suppl 1):S52–S57. doi: 10.1111/j.1526-4610.2007.00677.x. [DOI] [PubMed] [Google Scholar]
- 5.Lacoste M, Cai Y, Guicharnaud L, et al. Renal tubular dysgenesis, a not uncommon autosomal recessive disorder leading to oligohydramnios: role of the renin–angiotensin system. J Am Soc Nephrol. 2006;17(8):2253–2263. doi: 10.1681/ASN.2005121303. [DOI] [PubMed] [Google Scholar]
- 6.Norwegian Medicines Agency. Summary of product characteristics (SPC), Atacand
- 7.Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–69. doi: 10.1001/jama.289.1.65. [DOI] [PubMed] [Google Scholar]
- 8.Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322(7277):19–22. doi: 10.1136/bmj.322.7277.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med. 2002;112(8):642–646. doi: 10.1016/s0002-9343(02)01100-2. [DOI] [PubMed] [Google Scholar]
- 10.Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache. 1995;35(8):470–471. doi: 10.1111/j.1526-4610.1995.hed3508470.x. [DOI] [PubMed] [Google Scholar]
- 11.Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res. 2004;27(6):441–446. doi: 10.1291/hypres.27.441. [DOI] [PubMed] [Google Scholar]
- 12.Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–762. doi: 10.1212/wnl.55.6.754. [DOI] [PubMed] [Google Scholar]
- 13.Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine—report of an EFNS task force. Eur J Neurol. 2006;13(6):560–572. doi: 10.1111/j.1468-1331.2006.01411.x. [DOI] [PubMed] [Google Scholar]
- 14.Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Phys. 2006;73(1):72–78. [PubMed] [Google Scholar]
- 15.Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust. 2008;189(5):283–288. doi: 10.5694/j.1326-5377.2008.tb02028.x. [DOI] [PubMed] [Google Scholar]
- 16.Sanchez SI, Seltzer AM, Fuentes LB, Forneris ML, Ciuffo GM. Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. Eur J Pharmacol. 2008;588(1):114–123. doi: 10.1016/j.ejphar.2008.04.014. [DOI] [PubMed] [Google Scholar]
- 17.Guron G, Sundelien B, Wickman A, Friberg P. Angiotensin-converting enzyme inhibition in piglets induces persistent renal abnormalities. Clin Exp Pharmacol Physio. 1988;25(2):88–91. doi: 10.1111/j.1440-1681.1998.tb02182.x. [DOI] [PubMed] [Google Scholar]